Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080940 | 0.92 | MEN1 (0.31) | MEN1MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL3453582 | 0.91 | CDC7 (0.32) | MEN1MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL6160994 | 0.91 | KDM4E (0.32) | MEN1MAPTKMT2ACNR1CNR2 | |
| SCHEMBL6167207 | 0.88 | GPR142 (0.31) | ALDH1A1KDM4ELMNAHTTL3MBTL1 | |
| SCHEMBL6970653 | 0.86 | — | — | |
| SCHEMBL6973846 | 0.86 | — | — | |
| Carbamic Acid SCHEMBL4573817 | 0.85 | CDC7 (0.33) | ALDH1A1GSK3BCYP3A4 | |
| SCHEMBL5623524 | 0.85 | ALDH1A1 (0.30) | ALDH1A1KDM4ELMNAHTTL3MBTL1 | |
| SCHEMBL6160664 | 0.85 | TSHR (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL6973238 | 0.85 | CYP1A2 (0.33) | GSK3BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011077100-A1 | ANTIRETROVIRAL COMPOSITION | CIPLA LIMITED (IN) | 2011-06-30 | — | — | WO | claimed |
| US-20110105477-A1 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-05-05 | — | — | US | claimed |
| WO-2009036341-A2 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-03-19 | — | — | WO | claimed |
| US-11938166-B2 | Methods and compositions for treating mucosal tissue disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3676252-B1 | DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE | CHULABHORN FOUND (TH) | 2023-11-29 | — | — | EP | disclosed |
| US-20220143129-A1 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERS | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2022-04-14 | — | — | US | disclosed |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | CIPLA LIMITED (IN) | 2022-02-01 | — | — | US | disclosed |
| US-11058743-B2 | Methods and compositions for treating mucosal tissue disorders | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-07-13 | — | — | US | disclosed |
| US-10889566-B2 | Derivatives and composition of quinoline and naphthyridine | CHULABHORN FOUNDATION (TH) | 2021-01-12 | — | — | US | disclosed |
| US-20200223820-A1 | DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE | CHULABHORN FOUNDATION (TH) | 2020-07-16 | — | — | US | disclosed |
| EP-1175224-A2 | PEGYLATED INTERFERON ALFA-CCR5 ANTAGONIST COMBINATION HIV THERAPY | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1175402-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| US-20020004584-A1 | HIV immune adjuvant therapy | LAUGHLIN MARK A (US) | 2002-01-10 | — | — | US | disclosed |
| WO-2001066132-A2 | HIV IMMUNE ADJUVANT THERAPY | SCHERING CORPORATION (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2000066141-A2 | PEGYLATED INTERFERON ALFA-CCR5 ANTAGONIST COMBINATION HIV THERAPY | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066559-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-1034790-A2 | HIV therapy | SCHERING CORPORATION (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000051631-A2 | PEGYLATED ALPHA INTERFERON FOR HIV THERAPY | SCHERING CORPORATION (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105477-A1 | COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION | PREP, HPN, PEPD | MEN1 4084/4885MAPT 1185/4885KMT2A 3756/4885 |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | PAICS, HAVCR2, THPO | MEN1 2913/4885MAPT 1442/4885KMT2A 2946/4885 |
| US-10889566-B2 | Derivatives and composition of quinoline and naphthyridine | MCL1, TOP1, NQO2 | MEN1 524/4885MAPT 1916/4885KMT2A 2110/4885 |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | MEN1 2913/4885MAPT 1442/4885KMT2A 2946/4885 |
| US-20200223820-A1 | DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE | C1R, CBR3, CBR1 | MEN1 2930/4885MAPT 4555/4885KMT2A 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.